Clinical Trial Update: Efficacy and Safety of the Biosimilar Natalizumab PB006 in Comparison to Tysabri® [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating the efficacy and safety of the biosimilar PB006 versus Tysabri in relapsing-remitting multiple sclerosis has completed with results pos…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• PB006 (polpharma biosimilar natalizumab)
• Tysabri (Natalizumab)

Snippet

Sponsor: Polpharma Biologics S.A. | Conditions: Relapsing-Remitting Multiple Sclerosis (RRMS) | Phase 3 | Status: COMPLETED | Results posted: 2023-07-03